Search | Clinical Trials Finder

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: BeCare application; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: East Hanover, New Jersey • Marlton, New Jersey

Conditions: Multiple Sclerosis
Interventions: Natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions: Daclizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Tampa, Florida • Des Moines, Iowa • Milwaukee, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 10
States / cities: La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: abatacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 20
States / cities: Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Ofatumumab, Disease modifying treatment (DMT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more

Conditions: Multiple Sclerosis
Interventions: Copaxone®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Cullman, Alabama • Carmichael, California • Atlanta, Georgia + 11 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 32
States / cities: Cullman, Alabama • Sun City, Arizona • Tucson, Arizona + 29 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B; Other
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 67
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Multiple Sclerosis, Myasthenia Gravis
Interventions: CC-97540, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 13 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 26
States / cities: Irvine, California • Sunnyvale, California • Aurora, Colorado + 23 more

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: New Formulation of rebif - human interferon beta-1a, Interferon beta -1b; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Bazedoxifene Acetate; Drug
Lead sponsor: Riley Bove, MD; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Acthar Gel, Placebo; Drug
Lead sponsor: Mallinckrodt ARD LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more

Conditions: Multiple Sclerosis, RRMS
Interventions: Observational; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 5
States / cities: San Francisco, California • Torrance, California • Iowa City, Iowa + 2 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta 1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Vatelizumab, Placebo (for Vatelizumab); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BAF312; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Miami, Florida • Pompano Beach, Florida • Tallahassee, Florida + 5 more

Search by objective public record fields.

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

Adherence Trial With MS LifeLines ® Services

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

RNF and Betaseron® Tolerability Study

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis